Alerta

MACHINE LEARNING MODELS FOR DETECTING OUTLIERS AND ERRONEOUS SENSOR USE CONDITIONS AND CORRECTING, BLANKING, OR TERMINATING GLUCOSE SENSORS

Absstract of: US20260204414A1

Techniques disclosed herein relate to sensor data. In some embodiments, the techniques may involve obtaining sensor data. The techniques may further involve applying, to the sensor data, a machine learning model trained to identify outlier measurements. The techniques may further involve determining, based on output from the machine learning model, that the sensor data corresponds to an outlier measurement. The techniques may further involve blanking the sensor data based on the output.

Smart Footwear, Insoles or Other Wearables with Electronically Read Sensing Membrane and Self-Identification of Left/Right Status

Absstract of: US20260198800A1

Wearable smart devices are disclosed that incorporate a unique means of detecting or measuring a substance of interest, for example to detect ammonia in the secreted foot sweat of a diabetic via incorporation of the sensing arrangement in a footwear article or insole. The setup employs the combination of a colour-changing sensing membrane responsive to the substance of interest, an optical sensor appropriately positioned to capture the membrane within its field of view, and an illumination means for illuminating the membrane to enable optical imaging thereof, from which a controller can then detect the colour of the membrane and determine the presence or measurement of the substance of interest. A left/right self-identification circuit is included in each wearable smart device to enable a cooperative pair of such devices, worn on different bilateral appendages, to self-identify their left/right designation to the external device that receives the outputted signals from the wearables.

INDUCTIVE CHARGING OF AN INFUSION PUMP

Absstract of: US20260199590A1

A user-wearable patch pump system for delivery of insulin or other medicament can include a patch pump having a reusable drive unit and a replaceable and refillable cartridge. The cartridge can selectively attach to and be detached from the drive unit. The cartridge can initially be inserted onto the drive unit in a first orientation at an angle to the drive unit and then be rotated to align the cartridge with the drive unit and lock the cartridge in place on the drive unit to form the patch pump.

METHOD OF INDUCING UMBILICAL CORD MESENCHYMAL STEM CELLS TO DIFFERENTIATE INSULIN-LIKE CELLS AND AN APPLICATION THEREOF

Absstract of: US20260201338A1

A method of inducing umbilical cord mesenchymal stem cells to differentiate insulin-like cells and an application thereof, the invention carries out reasonable culture of purified umbilical cord mesenchymal stem cells by adopting culture medium having different substances, and can efficiently and stably induce them to differentiate into insulin-like cells, and the percentage of insulin-positive cells can reach 80%. The cell preparation prepared after induction of umbilical cord mesenchymal stem cells of the invention can be used for the treatment of clinical diabetic patients with high therapeutic efficacy.

LINEAR TIME-VARYING MODEL PREDICTIVE CONTROL OF AN ARTIFICIAL PANCREAS WITH BLOOD GLUCOSE PREDICTORS

Absstract of: WO2025054131A1

A blood glucose monitoring system having an insulin pump operational to administer insulin to the subject, sensors associated with the subject and operational to measure the blood glucose levels of a subject, and a computing device in electronic communication with the insulin pump. The computing device includes computer readable storage mediums having program code embodied therewith. The computing device includes a closed-loop insulin delivery algorithm trained to predict the blood glucose level of the subject. The algorithm includes a data-driven multi-step- ahead blood glucose predictor integrated with a linear time-varying model predictive control law. The computing device includes programming instructions for feeding the subject's blood glucose level into the algorithm, using the algorithm to predict if the blood glucose level of the subject is expected to reach a level representing hypoglycemia or hyperglycemia, and transmitting insulin administration instructions to the insulin pump based on the prediction.

DEVICE FOR COLLECTION OF VOLATILE COMPOUNDS FROM SKIN FOR NON-INVASIVE MEASUREMENT OF BLOOD-GLUCOSE VALUES

Absstract of: WO2021167918A1

A volumetric sampling apparatus for volatile compounds comprises a structure, such as a channel structure that forms a continuous curve between the inlet port and the outlet port. A gas flow induced in the structure urges volatile compounds collected via transdermal diffusion toward the outlet port, where the volatile compounds may be collected and analyzed.

SYSTEM AND METHOD FOR TITRATING BASAL INSULIN DOSES

Absstract of: US20260192048A1

0000 A continuous glucose monitor (CGM)-driven basal insulin titration system and method for patients with Type 2 Diabetes can be adapted to the needs and concerns of subjects just starting on basal insulin therapy. The method uses as inputs historical CGM data, basal insulin dose information, reports of hypoglycemia, and past recommendations and generates an adjusted insulin dose along with a report advising whether to continue the titration process, or to stop. The method can generate a new recommendation on a regular basis (e.g., each day) until it determines an adequate, consistent dose size.

MITIGATION OF COMPRESSION EVENT FAILURE FOR CONTINUOUS GLUCOSE MONITORS

Absstract of: AU2024395288A1

Certain aspects of the present disclosure relate to methods and systems for distinguishing between temporary compression of a sensor of a continuous analyte monitoring system and failure of the sensor, such as due to detachment of the sensor. In certain aspects, an apparatus includes an analyte sensor, a temperature sensor, a memory, and a processor communicatively coupled to the memory. The processor is configured to evaluate samples of an output of the analyte sensor and samples of an output of the temperature sensor with respect to a threshold condition. If the threshold condition is met, the processor is configured to generate a signal indicating failure of the analyte sensor.

GLUCOSE LEVEL DEVIATION DETECTION

Absstract of: US20260191435A1

0000 Glucose level measurements of a user are obtained over time, such as from a wearable glucose monitoring device being worn by the user. These glucose level measurements can be produced substantially continuously, such that the device may be configured to produce the glucose level measurements at regular or irregular intervals of time, responsive to establishing a communicative coupling with a different device, and so forth. These glucose level measurements are analyzed to detect deviations from past glucose measurements, such as glucose measurements received earlier in the day or glucose measurements received at corresponding times of one or more preceding days. Indications of detected deviations are provided to the user or communicated elsewhere, such as to a healthcare professional.

HEALTH EDUCATION-INTEGRATED LAUGHTER YOGA EXERCISE INTERVENTION TRAINING METHOD FOR DIABETIC FOOT PATIENTS

Absstract of: LU604632B1

The present invention provides a health education-integrated laughter yoga exercise intervention training method for diabetic foot patients, including: acquiring, in real time, multimodal physiological data of the patient including foot physiological parameters, systemic physiological indicators, and laughter audio signals; determining the patient’s current physiological context in real time based on the data, and dynamically generating a comprehensive intervention strategy; the strategy includes laughter yoga exercise instructions, context-embedded health education content, distributed proprioceptive guidance instructions for real-time posture adjustment guidance, and acoustic resonance induction instructions for emotional regulation; executing the strategy, and performing adaptive adjustment on the decision-making model for generating the strategy according to changes in physiological data after intervention. By constructing a closed-loop system of sensing, decision-making, execution, and feedback, the present invention is capable of providing patients with personalized, safe and dynamically adaptive rehabilitation training programs, achieving the coordinated rehabilitation of physical and psychological states.

RESPIRATORY THERAPY CONFIGURATION BASED ON GLUCOSE MONITORING AND METABOLIC HEALTH

Absstract of: WO2026148099A1

Techniques for improved respiratory therapy are provided. Glucose data of a user collected during a sleep session is accessed. Based at least in part on the glucose data, a plurality of transitions between sleep stages experienced by the user during the sleep session is determined. A sleep quality measure for the sleep session is generated based at least in part on the plurality of transitions. An apnea risk score for the user is generated based at least in part on the sleep quality measure, and one or more medical interventions for the user are provided based on the apnea risk score.

SYSTEMS, DEVICES, AND METHODS FOR MEAL INFORMATION COLLECTION, MEAL ASSESSMENT, AND ANALYTE DATA CORRELATION

Absstract of: US20260191433A1

Systems, devices, and methods for detecting, measuring and classifying meals for an individual based on analyte measurements. These results and related information can be presented to the individual to show the individual which meals are causing the most severe analyte response. These results can be organized and categorized based on preselected criteria or previous meals and results so as to organize and present the results in a format with reference to glucose as the monitored analyte. Various embodiments disclosed herein relate to methods, systems, and software applications intended to engage an individual by providing direct and timely feedback regarding the individual's meal-related glycemic response.

RESPIRATORY THERAPY CONFIGURATION BASED ON GLUCOSE MONITORING AND METABOLIC HEALTH

Absstract of: WO2026148093A1

Techniques for improved respiratory therapy are provided. Glucose data of a user, collected while the user was awake, is accessed, where the user is a participant in a respiratory therapy. A metabolic health (MH) state of the user is determined based at least in part on the glucose data. A respiratory therapy configuration for a subsequent usage session of the user is generated based on evaluating the MH state using one or more MH models. A respiratory therapy flow generator of the user is instructed to implement the respiratory therapy configuration during a usage session.

Multi-State Engagement With Continuous Glucose Monitoring Systems

Absstract of: US20260191434A1

Multi-state engagement with continuous glucose monitoring (CGM) systems is described. Given the number of people that wear CGM systems and because CGM systems produce measurements continuously, a platform that provides a CGM system may have an enormous amount of data. This amount of data is practically, if not actually, impossible for humans to process. In implementations, a CGM platform includes a data analytics platform that obtains packages of glucose measurements provided by a CGM system and also obtains additional data associated with a user. The data analytics platform generates state information for the user by processing these CGM packages and the additional data, at least in part, by using one or more models. Based on this state information, the data analytics platform controls communication with the user, which may include generating intervention strategies to prevent users from transitioning to a negative state such as discontinuing use of the CGM system.

MEDICAMENT DELIVERY SYSTEM USING LACTATE DATA

Absstract of: WO2026147654A1

A method of delivering a medicament to a subject for the treatment of diabetes includes: receiving glucose data and lactate data for the subject; adjusting medicament therapy to be delivered to the subject based at least in part on the glucose data and the lactate data; and delivering the adjusted medicament therapy to the subject.

SYSTEM AND METHOD FOR DECISION SUPPORT USING LIFESTYLE FACTORS

Absstract of: US20260192043A1

0000 Systems and methods are provided relating to open loop decision-making for management of diabetes. People with diabetes face many problems in controlling their glucose because of the complex interactions between food, insulin, exercise, stress, activity, and other physiological and environmental conditions. Established principles of management of glucose sometimes are not adequate because there is a significant amount of variability in how different conditions impact different individuals and what actions might be effective for them. Accordingly, systems and methods according to present principles minimize the impact of the vagaries of diabetes on individuals, i.e., by looking for patterns and tendencies of an individual and customizing the management to that individual. Consequently, the same reduces the uncertainty that diabetes typically is associated with and improves quality of life.

A NEW SITE FOR TRANSPLANTATION

Absstract of: US20260191912A1

Methods for transplanting cells or tissues, in particular islets, into a sub-rectus sheath site. Methods for treating diabetes by transplanting islets, particularly hPSC-islets, into a sub-rectus sheath position. The sub-rectus sheath position is a new site for transplantation.

ACID-ALPHA GLUCOSIDASE VARIANTS AND USES THEREOF

Absstract of: AU2026204844A1

The present invention relates to variants of acid-alpha glucosidase and uses thereof. un u n

SYSTEMS AND METHODS FOR USING CONTINUOUS KETONE MONITORING TO PROVIDE FITNESS OPTIMIZATION AND DISEASE DIAGNOSIS

Absstract of: WO2026147609A1

Certain aspects of the present disclosure provide a therapy management system configured to monitor analyte levels of a host during a time period using one or more analyte sensors to obtain analyte data, the analyte levels comprising at least glucose levels and ketone levels, and determine a metabolic fitness of the host based, at least in part, on the analyte data. The therapy management system is further configured to provide therapy management guidance to the host based, at least in part, on the determined metabolic fitness to improve the metabolic fitness of the host. The therapy management guidance includes at least one of a diet or meal recommendation for the host, an exercise recommendation for the host, or a lifestyle recommendation for the host.

Growth factor substituents

Absstract of: GB2644972A

Growth-enhancing peptides and fusion polypeptide are provided. The peptides and fusion polypeptides may be used in cell culture, in particular in the production of cultured meat, as replacement or addition to insulin. There is further provided a cell culture medium comprising at least one of the peptides or fusion polypeptides, and a method for growing cells comprising adding at least one of the peptides or polypeptides to the cell culture medium.

BIOELECTRODE, BIOELECTRODE PRODUCTION METHOD, ELECTROCHEMICAL DEVICE, BLOOD SUGAR LEVEL MEASUREMENT DEVICE, AND CONCENTRATION MEASUREMENT METHOD

Absstract of: EP4773258A1

A bioelectrode includes: a complex compound including a metal and a ligand; a mediator having an anionic functional group; and a conductive material.

SENSOR FOR DETECTING GLUCOSE AND LACTATE AND METHODS FOR DETERMINING AEROBIC AND ANAEROBIC THRESHOLDS

Absstract of: US2025169728A1

The present disclosure describes lactate-responsive sensors, sensing systems incorporating a lactate-responsive sensor, and methods of use thereof that would be beneficial for continuously monitoring lactate levels and determining lactate thresholds (both aerobic and anaerobic thresholds). The present disclosure also relates to an analyte sensor for continuously detecting glucose and lactate levels.

COMPOSITION FOR BASAL MEDIUM FOR ANIMAL CELL CULTURE

Absstract of: EP4772611A1

The present invention relates to a basal medium composition for animal cells. The basal medium composition for animal cells according to the present invention contains a yeast extract, amino acids, an inorganic salt, and a sugar, wherein the amino acids in the composition include cystine and/or cysteine, and glutamine.

BLOOD GLUCOSE DISEASE MANAGEMENT SYSTEM

Absstract of: US20260182931A1

0000 The disease management system can determine a measurement of one or more physiological parameters and can determine a disease event based on the one or more measurements. Furthermore, the disease management system can determine a pose of an individual using a pose sensor. Based on an identification of a disease event and a determination that the pose of the individual corresponds to a first pose, the disease management system can cause at least one of an audible, visual, or vibratory alarm. Based on an identification of a disease event and a determination that the pose of the individual does not correspond to the first pose, the disease management system can cause administration of a medication to the individual.

ARTIFICIAL PANCREAS INTEGRATED CGM ARCHITECTURES AND DESIGNS

Nº publicación: US20260183483A1 02/07/2026

Applicant:

ABBOTT DIABETES CARE INC [US]
Abbott Diabetes Care Inc.

Absstract of: US20260183483A1

0000 A system for managing a patient's glucose level includes a glucose sensor to generate and store data signals for measurements of the patient's glucose level made by the glucose sensor; an insulin pump; and sensor electronics operatively coupled to the glucose sensor, the sensor electronics comprising a memory storing one or more predetermined characteristics associated with the sensor electronics; and a computing device in electronic communication with the sensor electronics. The computing device comprises a processor configured to operate the sensor electronics to (i) receive the generated data signals, (ii) obtain the one or more predetermined sensor characteristics from the memory and (iii) execute a closed-loop algorithm to provide insulin delivery instructions to an insulin pump by at least using the data signals and predetermined characteristics.